Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer

Pancreatic cancer is a recalcitrant disease. Gemcitabine (GEM) is the most widely-used first-line therapy for pancreatic cancer, but most patients eventually fail. Transformative therapy is necessary to significantly improve the outcome of pancreatic cancer patients. Tumors have an elevated requirem...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cell Cycle
Main Authors: Kawaguchi, Kei, Miyake, Kentaro, Han, Qinghong, Li, Shukuan, Tan, Yuying, Igarashi, Kentaro, Lwin, Thinzar M., Higuchi, Takashi, Kiyuna, Tasuku, Miyake, Masuyo, Oshiro, Hiromichi, Bouvet, Michael, Unno, Michiaki, Hoffman, Robert M.
Formato: Artigo
Idioma:Inglês
Publicado: Taylor & Francis 2018
Assuntos:
Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6056209/
https://ncbi.nlm.nih.gov/pubmed/29623758
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2018.1445907
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares